Kodiak Sciences (Kodiak Sciences) EBIT : $-260.48 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences EBIT?

Kodiak Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-59.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-260.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kodiak Sciences's annualized ROC % for the quarter that ended in Dec. 2023 was -125.01%. Kodiak Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -133.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kodiak Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 712.64%.

Kodiak Sciences EBIT Historical Data

The historical data trend for Kodiak Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences EBIT Chart

Kodiak Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-47.36

-133.07

-266.94

-333.81

-260.48

Kodiak Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-70.44	-70.78	-80.18	-50.00	-59.52

Competitive Comparison of Kodiak Sciences's EBIT

For the Biotechnology subindustry, Kodiak Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's EV-to-EBIT falls into.

Kodiak Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-260.48 Mil.

Kodiak Sciences (NAS:KOD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kodiak Sciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-253.496 * ( 1 - 0% )	/	( (205.74	+	199.833)	/ 2 )
=	-253.496	/	202.7865
=	-125.01 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	547.652	-	61.759	-	( 345.668	-	max(0, 70.774	-	350.927	+	345.668	))
=	205.74

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	479.372	-	31.959	-	( 285.507	-	max(0, 41.729	-	289.309	+	285.507	))
=	199.833

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kodiak Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-238.064	/	( ( (181.669 + max(-56.5, 0))	+	(175.023 + max(-28.157, 0)) )	/	2 )
=	-238.064	/	( ( 181.669	+	175.023 )	/	2 )
=	-238.064	/	178.346
=	-133.48 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.259)	-	(61.759	+	0	+	0)
=	-56.5

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.802)	-	(31.959	+	0	+	0)
=	-28.157

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kodiak Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-260.478	/	-36.551
	=	712.64 %

Kodiak Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences (Kodiak Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

K27:Germany

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Executives

Jason Ehrlich	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth	director, 10 percent owner, officer: Chairman, President and CEO	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang	officer: See Remarks	2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek	director	P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016